How robust are the results of one of the first positive trials exploring hydroxychloroquine for treatment of COVID-19?

Abstract

An outbreak of a novel human coronavirus infection emerged in Wuhan, China in December 2019. Two months later, the World Health Organization (WHO) announced SARS-CoV-2 as the name for the new virus and COVID-19 for the associated illness. On March 12, 2020, the WHO officially declared COVID-19 as a pandemic. The scientific community has raced to find effective therapeutic agents against the virus. Gautret et al 2020 is among one of the first purportedly positive trials of hydroxychloroquine for the treatment of COVID-19. However, it is imperative that a thorough analysis and understanding of trial data be undertaken prior to making claims about safety and efficacy. Our group assessed the statistical robustness of the trial using the Fragility Index (FI). The FI provides a numerical quantification of a clinical trial's conclusions. The index is based on iterative statistical calculations to determine the minimum number of events within a trial that would theoretically need to change from positive to negative in order for the trial's endpoint to convert from significant to non-significant; the higher the index, the more statistically robust the study results. For the Gautret et al trial, one endpoint had an FI of 1, two had indices of 2, and another had an index of 4. The primary endpoint of viral clearance on day 6 had an FI of 4. This indicates that if 4 events were to change from positive to negative, the conclusion of the trial would become mathematically non-significant. This index is comparable to many other published trials of established agents; the median FI across the reported literature appears to be 2. In conclusion, the trial results reported by Gautret et al are statistically robust, assuming that data quality is not compromised; however, the study was an open-label trial with non-homogenous groups, with analysis conducted per-protocol.Additionally, SARS-CoV-2 Reverse Transcriptase-PCR (RT-PCR) testing was not conducted in a systematic way amongst the two groups. Further analyses of this trial and future trials of All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis

“…In December 2019, the first outbreak of a novel human coronavirus infection named severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China [ 1 ]. The SARS-CoV-2 then rapidly spread across the globe, manifesting a high incidence of COVID-19 disease; on March 12, 2020, the World Health Organization declared COVID-19 as a pandemic [ 2 ].…”

The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis

“…Corresponding 95% confidence intervals (CI) for an OR or a HR are reported as well. When there was heterogeneity of I 2 of equal to or greater than 50%, a random-effects DerSimonian-Laird analysis model was applied; otherwise, a fixed-effects inverse-variance analysis model was used. A p -value of less than 0.05 was considered statistically significant.…”

Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients

“…The COVID-19 pandemic, as declared by the World Health Organization on March 12, 2020 (1), has been an ongoing global health and social crisis for the past one-and-a-half years. Many potential treatments have been explored, including statins.…”